GlassScriptPhysician profile
Beth A Lopez
NPI 1073626016
$12,953.00
in general payments reported to CMS, 2019-2025
31 companies · $2,515 in 2025
The $2,515 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,580 · 2022: $2,782 · 2023: $2,936 · 2024: $3,140 · 2025: $2,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,500 · Education: $90.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,499.65 |
| Education | $90.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,670.60 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $1,368.30 | 2021-2025 | |
| Janssen Biotech, INC. | $1,256.65 | 2021-2025 | Tremfya, Simponi, Remicade |
| Genzyme Corporation | $1,243.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,145.19 | 2021-2025 | |
| Dermavant Sciences, INC. | $652.15 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $643.79 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $582.42 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $575.80 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $558.04 | 2021-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $549.60 | 2021-2025 | |
| Incyte Corporation | $491.10 | 2021-2025 | Opzelura |
| Pfizer INC. | $423.85 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $352.02 | 2023-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $231.39 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $214.42 | 2023-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.53 | 2021-2022 | |
| Kyowa Kirin, INC. | $138.39 | 2022-2025 | Poteligeo |
| Mayne Pharma Commercial LLC | $119.15 | 2022-2025 | |
| Almirall LLC | $110.56 | 2021-2025 | Seysara, Klisyri |
| Hill Dermaceuticals, INC. | $88.21 | 2023-2024 | Tolak |
| Galderma Laboratories, L.P. | $78.32 | 2021-2025 | |
| Organon LLC | $58.52 | 2025 | Vtama |
| Botanix Sb INC | $56.81 | 2025 | Sofdra |
| Genentech USA, INC. | $43.67 | 2021 | |
| Biowound Solutions, INC. | $43.63 | 2025 | Bio-Connekt |
| Vyne Pharmaceuticals INC. | $24.45 | 2021 | |
| Biofrontera INC. | $21.60 | 2022 | |
| Boston Scientific Corporation | $16.78 | 2022 | |
| Tactile Systems Technology INC | $12.96 | 2022 | |
| Stemline Therapeutics INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.